Cash in on tomorrow's feel-good factor

Article Abstract:

Lifestyle drugs represent an important market for pharmaceutical companies, though governments in developed economies may see them as increasing healthcare budgets. They are drugs to treat conditions linked to modern lifestyles and the impact of ageing, and include contraceptives and obesity treatments. The pharmaceutical industry faces increased competition and shorter product lifecycles, so companies cannot afford to ignore lifestyle drugs. Pfizer's Viagra is an example of the potential in terms of profits that lifestyle drugs can offer.

Drugs, Economic aspects

---

Astra: drug dealing

Article Abstract:

Astra is acquiring research and development facilities from Fisons in the UK for 202 million pounds sterling. The company should solve the problems of the need to boost its product schedule through this acquisition. Fisons operates in a similar product area to Astra, with both specialising in treatments for the central nervous system and respiratory and cardiovascular problems. Fisons has lacked cash to develop products, while Astra has been unable to match research to its growth in other areas.

Respiratory Preparations, Medicinal and Botanical Manufacturing, Bulk Nervous System Drugs, Bulk Cardiovascular Drugs, Mergers, acquisitions and divestments, Astra AB, Respiratory system agents, Bulk drugs, Cardiovascular agents, Fisons PLC, Nervous system agents

---

Drug groups eye Japan

Article Abstract:

Oral contraceptives may be legalized in Japan and this would open a market for foreign drug companies. The Central Pharmaceutical Affairs Council has put the case for permitting oral contraceptives. Companies interested in this market include Akzo, Schering and American Home Products. Yamanouchi and Schering have set up a marketing agreement which will be effective if rules are eased. The market is likely to grow slowly if approval is granted.

Oral Contraceptives, Japan, Laws, regulations and rules, Contraceptive drugs

Similar abstracts:

• Abstracts: Competition between goods and services: setting the research agenda
• Abstracts: At work in the field called fashion. Fresh quaint
• Abstracts: The non-practitioner's view. Chartered: the premium brand. Where members' money goes
• Abstracts: Thumbs up for Glaxo. Drug deal uncertain. Harsh medicine boosts Fisons' prospects
• Abstracts: Building materials: still tough. Life gets tough in the builders' yards. Baris: recovery punt

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.